Back to search results
NCT06061328

Project OASIS: Optimizing Approaches to Select Implementation Strategies

Enrolling by Invitation
NAAges 18+InterventionalHealth services
VA Office of Research and Development
~8,020 participants
Updated 2026-02-04 on ClinicalTrials.gov
What's tested:OASIS DA trainingCurrent DA Tool training

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Reach as assessed by hepatocellular carcinoma (HCC) screening rates
Measured over measured quarterly 1 year pre-intervention through 6 months post-intervention
+4 more outcomes measured

Conditions

Cirrhosis
Hepatocellular Carcinoma

Explore related trials

Cirrhosis

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Shari S Rogal, MD MPH · PRINCIPAL_INVESTIGATOR · VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Veterans with two outpatient or one inpatient codes for cirrhosis or its complications who had an encounter in the prior 18 months at a participating VA medical center
Physicians, advance practice providers, nurses, leadership, and staff engaged with selecting and applying implementation strategies to improve care at a participating VA medical center

Exclusion

Veterans post-transplant or with active hepatocellular carcinoma

What this trial measures

  • Reach as assessed by hepatocellular carcinoma (HCC) screening ratesmeasured quarterly 1 year pre-intervention through 6 months post-intervention

    Reach of an intervention refers to the absolute number, proportion, and representativeness of individuals who are willing to participate in a given intervention. The reach outcome will be the percentage of active VA patients with a diagnosis of cirrhosis receiving guideline-concordant abdominal imaging every 6 months.

  • Effectiveness as assessed by patient outcomesmeasured quarterly 1 year pre-intervention through 6 months post-intervention

    Effectiveness is the impact of an intervention on important individual outcomes. Patient outcomes such as cancers detected and linkage to curative treatment will be used to assess effectiveness.

  • Adoption as assessed by % improvement in HCC screening performancemeasured quarterly 1 year pre-intervention through 6 months post-intervention

    Adoption is the absolute number, proportion, and representativeness of settings/people who are willing to initiate a program. The investigators will assess adoption by the percent improvement in screening performance at intervention sites from pre- to post-intervention.

  • Implementation as assessed by fidelity to HCC screening recommendationsmeasured quarterly 1 year pre-intervention through 6 months post-intervention

    Implementation is the extent to which an intervention is delivered as intended. The investigators will assess implementation by the proportion of patients at an intervention site receiving all hepatocellular carcinoma screening as recommended (correct timing and modality).

  • Maintenance as assessed by maintenance of other measures6 months post-intervention

    Maintenance is the extent to which a program becomes part of routine organizational practices. The investigators will assess maintenance by sustainment of all above outcomes at 6 months post-intervention.